≥99% HPLCPre-filled pen

Thymosin Alpha 1

Name: Thymosin Alpha 1
Brand: Dripfy
Availability: InStock

What it is?

Thymosin Alpha 1 is an immune-modulating peptide studied for enhancing T-cell function and coordinating immune signalling. It is positioned for protocols focused on immune resilience, surveillance, and balanced immune response dynamics, which are increasingly recognised as core determinants of healthy ageing.

Dripfy Advantage

T-cell maturation support: Stimulates pathways associated with T-cell development and functional activation, supporting adaptive immunity endpoints.
Immune-response modulation: Helps regulate immune response dynamics to pathogens and cellular abnormalities, supporting balanced immune signalling.
Antigen processing enhancement: Associated with improved antigen recognition and processing pathways relevant to immune surveillance frameworks.
Inflammation balance: Often positioned where immune activation is desired without excessive inflammatory signalling, supporting immune equilibrium.
Healthspan relevance: Integrates immune competence into longevity protocols, reflecting the role of immunity in long-term functional preservation.

Clinical Applications & Therapeutic Potential

Immune surveillance endpoints: Potential support for enhanced immune monitoring and response markers in resilience-focused protocols.
Infection resilience: Potential improvements in resistance-to-infection endpoints and recovery robustness markers.
Balanced immune function: Positioned for immune regulation frameworks where stability (not overactivation) is the core objective.
Longevity support via immune health: Potential contribution to healthspan through improved immune competence and reduced age-related immune decline markers.

Composition & Formulation

Peptide Content: 5 mg Thymosin Alpha-1
Vehicle: Proprietary pH-balanced buffer solution
Delivery System: Pre-filled, multi-dose, closed-system pen
Total Volume: 3 mL
Purity: ≥99% by HPLC/MS

€578

Order by email

Submit an enquiry and we arrange the consultation, physician review and shipping. Physician recommendation required; not medical advice.

Purity: ≥99%
Form: Pre-filled pen
Download Certificate of Analysis: Certificate of Analysis available on request

Important medical notice

A physician recommendation is mandatory before use.
The information on this website is educational only and is not medical advice, diagnosis, or treatment.
Always consult a qualified physician before starting any peptide.
Dosing is individualised and determined by your treating physician.

Peptide Practice Guide

Each card summarises what the peptide is studied for and its evidence strength. It is not a recommendation. Dosing and suitability are decided by your physician.

Thymosin Alpha 1

Thymic peptide immunomodulator (synthetic thymalfasin) · Pre-filled pen

B· Moderate evidence

Thymosin Alpha 1 is a synthetic version of a naturally occurring thymic peptide that helps orchestrate the maturation and activity of T-lymphocytes and dendritic cells. It is thought to act in part through Toll-like receptor signalling, nudging the immune system toward more coordinated responses to pathogens and abnormal cells. Research and clinical interest focus on restoring balanced immune function rather than driving indiscriminate activation.

Studied use areas

Investigated as an adjuvant in chronic viral hepatitis frameworks
Studied for supporting immune responses in immunocompromised or vaccination-related settings
Explored for immune resilience in ageing and immunosenescence research
Examined in critical-illness and sepsis immune-restoration studies

Safety & status

Registered or approved as thymalfasin in some countries, but not licensed in the EU/UK, where it is considered investigational
Generally well tolerated in trials, with injection-site reactions among the effects reported
Immune-directed peptides may be inappropriate for people with autoimmune disease or on immunosuppressants without specialist review
It must only be used under physician supervision

⚕ Clinical note: This is educational information, not medical advice. Thymosin Alpha 1 has the strongest evidence in this group and is approved as thymalfasin in some countries, but it is not licensed in the EU/UK and remains investigational there. Its use, indications and suitability must be determined and monitored by a treating physician.

Evidence: Grade B — approved/registered as thymalfasin in some countries with clinical-trial support, but not licensed in the EU/UK · References: peer-reviewed clinical immunology and hepatology literature; regulatory and manufacturer product information for thymalfasin where registered; reviews of thymic peptides and immunomodulation